The potential of the human CD38-specific antibody daratumumab to improve the antimyeloma effect of novel multidrug therapies including patients refractory to lenalidomide or bortezomib.
Year: 2011
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: T. Mutis, M. de Weers, M. S. van der Veer, B. v. Kessel, J. M. Bakker, S. Wittebol, P. Parren, H. M. Lokhorst
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2565294276